Literature DB >> 30316949

Establishment of TUSMi005-A, an induced pluripotent stem cell (iPSC) line from a 32-year old Chinese Han patient with Bipolar Disorder (BD).

Ying Wang1, Qiang Fen2, Hongxiang Yu3, Haixia Qiu4, Xiquan Ma2, Ying Lei3, Jian Zhao5.   

Abstract

A 32-year old Bipolar Disorder (BD) male patient donated his Peripheral blood mononuclear cells (PBMC). The non-integrating episomal vector system used to reprogram PBMCs with the human OKSM transcription factors. The pluripotency of transgene-free iPSCs was confirmed by immunocytochemistry for pluripotency markers and by the ability of the iPSCs to differentiate spontaneously into 3 germ layers in vitro. In addition, the iPSC line displayed a normal karyotype. Our model might offer a good platform to further study the pathological mechanisms, to identify early biomarkers, and also for drug testing studies in BD. Resource table.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30316949     DOI: 10.1016/j.scr.2018.10.014

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  3 in total

1.  Episomal Induced Pluripotent Stem Cells: Functional and Potential Therapeutic Applications.

Authors:  Aline Yen Ling Wang; Charles Yuen Yung Loh
Journal:  Cell Transplant       Date:  2019-11-14       Impact factor: 4.064

Review 2.  Mental health dished up-the use of iPSC models in neuropsychiatric research.

Authors:  Rhiannon V McNeill; Georg C Ziegler; Franziska Radtke; Matthias Nieberler; Klaus-Peter Lesch; Sarah Kittel-Schneider
Journal:  J Neural Transm (Vienna)       Date:  2020-05-07       Impact factor: 3.575

3.  Going Back and Forth: Episomal Vector Reprogramming of Peripheral Blood Mononuclear Cells to Induced Pluripotent Stem Cells and Subsequent Differentiation into Cardiomyocytes and Neuron-Astrocyte Co-cultures.

Authors:  Victoria C de Leeuw; Conny T M van Oostrom; Sandra Imholz; Aldert H Piersma; Ellen V S Hessel; Martijn E T Dollé
Journal:  Cell Reprogram       Date:  2020-11-03       Impact factor: 1.987

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.